Pfizer Is Using AI to Discover Breakthrough Medicines
Pfizer scientists have been using artificial intelligence and supercomputing to bring new vaccines and medicines to patients faster.
The Confidence to Rise to Any Challenge: Pfizer’s 2021 ESG Report
Pfizer is integrating environmental, social and governance issues into core business practices and is seeking to make a measurable impact in key areas.
Pfizer’s Twelve Years of Dividend Increases
Pfizer paid its first quarter dividend on the company’s common stock in March, the company’s 333rd consecutive quarterly dividend.
On Rare Diseases Day, New Partnerships and Investments Could Deliver Potential Breakthroughs
Pfizer recently entered into a collaboration with biotechnology company Beam Therapeutics aimed at developing precision genetic medicines for rare diseases of the liver, muscles and central nervous system.
Using Viruses to Fight Cancer: A New Approach to Treating Solid Tumors
A new treatment technology being developed – oncolytic virus therapy – may lend hope for patients battling locally advanced or metastatic solid tumors.
A “Fundamentally Changed” Company: Pfizer Reports Strong 2021 Earnings
Variant-Based Vaccine Trial Key to Virus Vigilance
Pfizer and BioNTech have begun a trial of an Omicron-based COVID-19 vaccine.
Pfizer’s Roadmap for mRNA, A “Game-Changer Technology”
Pfizer’s mRNA roadmap includes an investigational vaccine for the flu and a potential improved vaccine for shingle.